프랄린캡슐 75mg
Pricing inquiry (see details)
▶ Manufacturer: Ilhwa Co., Ltd.
▶Sold by: Ilhwa Co., Ltd.
▶Insurance code : 640902350
▶Storage : Airtight container, store at room temperature (1~30℃)
This item has been added to your cart.
Should I order it along with the items in my shopping cart?
Check location
Check location
031-550-0100
+ Appearance Hard capsule with red-brown top and white bottom cap containing white powder + Active ingredient(s) pregabaline 75mg |
+ Administration and dose 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: A starting dose of 150mg/day of this drug may be administered. Based on response and tolerance in individual patients, dose may be increased to 300mg/day after 3 to 7 days. If necessary, dose may be increased to 600mg/day at 7-day intervals thereafter. 2) Central neuropathic pain Adults: A starting dose of 150mg/day of this drug may be administered. Based on response and tolerance in individual patients, dose may be increased to 300mg/day after 3 to 7 days. Dose may be increased to target dose of 600mg/day after 1 additional week. Reducing dose may be considered if patient does not exhibit tolerance at target daily dose. (See ‘4. Discontinuing administration’) 2. Epilepsy Adults: A starting dose of 150mg/day of this drug may be administered. Based on response and tolerance in individual patients, dose may be increased to 300mg/day after 3 to 7 days. If necessary, dose may be increased to 600mg/day at 7-day intervals thereafter. 3. Fibromyalgia Recommended dose of this drug for fibromyalgia is 300mg to 450mg/day. The starting dose for this drug is 75mg administered twice a day (150mg/day), and may be increased to 150mg twice a day (300mg/day) within a week based on efficacy and tolerance. In the case of patients who do not experience sufficient benefits at a dose of 300mg/day, dose may be increased to 225mg twice a day (450mg/day) within a week. Clinical trials were carried out at a dose of 600mg/day, but there is no evidence of additional benefits or sufficient tolerance at this dose. Considering dose-dependent adverse reactions, administration of doses in excess of 450mg/day is not recommended. 4. Discontinuing administration Based on current clinical experience, this drug must be discontinued gradually at intervals of at least 1 week. 5. Patients with renal impairment This drug is systemically circulated and excreted unchanged mainly through the kidneys. Clearance of this drug is directly impacted by creatinine clearance, and therefore dose reductions in patients with reduced renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined through the following formula. + Indications 1. Treatment of peripheral and central neuropathic pain in adults 2. Epilepsy Adjuvant for partial seizures in adults accompanied by or not accompanied by secondary systemic symptoms 3. Treatment of fibromyalgia |
+ Appearance Hard capsule with red-brown top and white bottom cap containing white powder + Active ingredient(s) pregabaline 75mg |
+ Administration and dose 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: A starting dose of 150mg/day of this drug may be administered. Based on response and tolerance in individual patients, dose may be increased to 300mg/day after 3 to 7 days. If necessary, dose may be increased to 600mg/day at 7-day intervals thereafter. 2) Central neuropathic pain Adults: A starting dose of 150mg/day of this drug may be administered. Based on response and tolerance in individual patients, dose may be increased to 300mg/day after 3 to 7 days. Dose may be increased to target dose of 600mg/day after 1 additional week. Reducing dose may be considered if patient does not exhibit tolerance at target daily dose. (See ‘4. Discontinuing administration’) 2. Epilepsy Adults: A starting dose of 150mg/day of this drug may be administered. Based on response and tolerance in individual patients, dose may be increased to 300mg/day after 3 to 7 days. If necessary, dose may be increased to 600mg/day at 7-day intervals thereafter. 3. Fibromyalgia Recommended dose of this drug for fibromyalgia is 300mg to 450mg/day. The starting dose for this drug is 75mg administered twice a day (150mg/day), and may be increased to 150mg twice a day (300mg/day) within a week based on efficacy and tolerance. In the case of patients who do not experience sufficient benefits at a dose of 300mg/day, dose may be increased to 225mg twice a day (450mg/day) within a week. Clinical trials were carried out at a dose of 600mg/day, but there is no evidence of additional benefits or sufficient tolerance at this dose. Considering dose-dependent adverse reactions, administration of doses in excess of 450mg/day is not recommended. 4. Discontinuing administration Based on current clinical experience, this drug must be discontinued gradually at intervals of at least 1 week. 5. Patients with renal impairment This drug is systemically circulated and excreted unchanged mainly through the kidneys. Clearance of this drug is directly impacted by creatinine clearance, and therefore dose reductions in patients with reduced renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined through the following formula. + Indications 1. Treatment of peripheral and central neuropathic pain in adults 2. Epilepsy Adjuvant for partial seizures in adults accompanied by or not accompanied by secondary systemic symptoms 3. Treatment of fibromyalgia |